Detoxification of the Liver In PSC (Dolphin)

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

BRS201

Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.

DRUG

Placebo

Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.

Trial Locations (1)

02467

RECRUITING

Brigham and Women's Hospital, Chestnut Hill

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER